US FDA issues complete response letter for Schering-Plough's Saphris
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas been issued a US FDAcomplete response letter regarding its antipsychotic Saphris (asenapine) sublingual tablets for the treatment of schizophrenia in adults and in acute bipolar I disorder in adults as a monotherapy.